ANDA 210599, held by Qingdao Baheal Pharm. Duloxetine Hydrochloride.
As of Nov 16, 2026, ANDA 210599 (Duloxetine Hydrochloride), held by Qingdao Baheal Pharm, was first approved by FDA on Apr 17, 2019, with 1 approved supplement and 0 published complete response letters.
Duloxetine delayed-release capsules are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 17, 2019 | Original application | Approved | None posted |
| Duloxetine HydrochlorideEQ 20MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Rx |
| Duloxetine HydrochlorideEQ 30MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Rx |
| Duloxetine HydrochlorideEQ 60MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Rx |
| May 2, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 17, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters